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Abstract: Here, we applied the designed ankyrin repeat protein (DARPin) technology to develop novel
gp120-directed binding molecules with HIV entry-inhibiting capacity. DARPins are interesting molecules
for HIV envelope inhibitor design, as their high-affinity binding differs from that of antibodies. DARPins
in general prefer epitopes with a defined folded structure. We probed whether this capacity favors the
selection of novel gp120-reactive molecules with specificities in epitope recognition and inhibitory activity
that differ from those found among neutralizing antibodies. The preference of DARPins for defined struc-
tures was notable in our selections, since of the four gp120 modifications probed as selection targets, gp120
arrested by CD4 ligation proved the most successful. Of note, all the gp120-specific DARPin clones with
HIV-neutralizing activity isolated recognized their target domains in a conformation-dependent man-
ner. This was particularly pronounced for the V3 loop-specific DARPin 5m3D12.InstarkcontrasttoV 3−
specificantibodies, 5m3D12preferentiallyrecognizedtheV 3loopinaspecificconformation, asprobedbystructurallyarrestedV 3mimeticpeptides, butboundlinearV 3peptidesonlyveryweakly.Mostnotably, thisconformation−
dependentV 3recognitionallowed5m3D12tobypasstheV 1V 2shieldingofseveraltier2HIV isolatesandtoneutralizetheseviruses.ThesedataprovideaproofofconceptthattheDARPintechnologyholdspromiseforthedevelopmentofHIV entryinhibitorswithauniquemechanismofaction.
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Here	  we	   applied	   the	  Designed	  Ankyrin	  Repeat	  Protein	   (DARPin)	   technology	   to	   develop	  novel	  27	  
gp120-­‐directed	   binding	  molecules	  with	   HIV	   entry-­‐inhibiting	   capacity.	   DARPins	   are	   interesting	  28	  
molecules	   for	  HIV	  envelope	   inhibitor	  design,	  as	   their	  high	  affinity	  binding	  differs	   from	  that	  of	  29	  
antibodies.	  DARPins	  in	  general	  prefer	  epitopes	  with	  a	  defined	  folded	  structure.	  Here	  we	  probed	  30	  
whether	  this	  capacity	  favors	  the	  selection	  of	  novel	  gp120-­‐reactive	  molecules	  with	  specificities	  31	  
in	  epitope	  recognition	  and	  inhibitory	  activity	  that	  differ	  from	  those	  found	  amongst	  neutralizing	  32	  
antibodies.	  The	  preference	  of	  DARPins	  for	  defined	  structures	  was	  notable	  in	  our	  selections	  as	  of	  33	  
the	   four	   gp120	   modifications	   probed,	   gp120	   arrested	   by	   CD4	   ligation	   proved	   the	   most	  34	  
successful	   panning	   target.	   	   Of	   note,	   all	   gp120	   specific	   DARPin	   clones	   with	   HIV	   neutralizing	  35	  
activity	   we	   isolated,	   recognized	   their	   target	   domains	   in	   a	   conformation-­‐dependent	   manner.	  36	  
This	  was	  particularly	  pronounced	  for	  the	  V3-­‐loop-­‐specific	  DARPin	  5m3_D12.	  In	  stark	  contrast	  to	  37	  
V3-­‐specific	   antibodies,	   5m3_D12	   preferentially	   recognized	   the	   V3	   loop	   in	   a	   specific	  38	  
conformation,	   as	   probed	   by	   structurally	   arrested	   V3	   mimetic	   peptides,	   but	   bound	   linear	   V3	  39	  
peptides	  only	  very	  weakly.	  Most	  notably,	  this	  conformation-­‐dependent	  V3	  recognition	  allowed	  40	  
5m3_D12	  to	  bypass	  V1V2	  shielding	  of	  several	  tier	  2	  HIV	  isolates	  and	  to	  neutralize	  these	  viruses.	  41	  
These	   data	   provide	   a	   proof	   of	   concept	   that	   the	   DARPin	   technology	   holds	   promise	   for	   the	  42	  




The	  highly	  specific	  interaction	  of	  the	  HIV	  envelope	  spike,	  a	  trimer	  composed	  of	  gp120	  and	  gp41	  45	  
heterodimers,	   with	   the	   cellular	   receptor	   CD4	   and	   a	   co-­‐receptor	   (typically	   CCR5	   or	   CXCR4)	  46	  
initiates	  HIV	  entry	  and	  is	  indispensable	  for	  infection	  (reviewed	  in	  (1)).	  Although,	  the	  potential	  of	  47	  
HIV	   entry	   blocking	   agents	   for	   intervention	   strategies	   has	   been	   acknowledged	   for	   long	   and	   a	  48	  
number	  of	  agents	  targeting	  the	  viral	  envelope	  proteins	  and	  the	  cellular	  receptors	  CD4,	  CCR5	  or	  49	  
CXCR4	   have	   been	   developed	   (2,	   3),	   thus	   far	   only	   two	   entry	   inhibitors,	   the	   peptidic	   fusion	  50	  
inhibitor	   T-­‐20	   targeting	   gp41	   (4)	   and	   the	   small	   molecule	   CCR5	   inhibitor	  Maraviroc	   (5),	   have	  51	  
been	  used	  clinically.	  52	  
Design	  of	   appropriate	   inhibitors,	   in	  particular	   those	  which	   target	   the	   viral	   envelope	  proteins,	  53	  
faces	   challenges	   which	   are	   in	   many	   aspects	   similar	   to	   those	   encountered	   by	   natural	   and	  54	  
vaccine-­‐induced	  antibody	  responses.	  Both	  neutralizing	  antibodies	  and	  inhibitors	  need	  to	  access	  55	  
vulnerable	  sites	  on	  the	  HIV	  envelope	  trimer.	  The	  complex	  quaternary	  structure	  of	  the	  trimeric	  56	  
envelope	   spike,	   however,	   efficiently	   shields	   functionally	   important	   domains.	   Conserved	  57	  
domains	  are	  positioned	  facing	  inwards	  in	  the	  trimeric	  complex,	  only	  to	  be	  exposed	  transiently	  58	  
upon	   receptor	   engagement	   (6-­‐8),	   while	   the	   outer	   trimer	   surface	   is	   protected	   by	   flexible,	  59	  
variable	  loops	  and	  extensive	  glycosylation	  (7,	  9-­‐11).	  These	  strategies	  act	  in	  concert	  to	  shield	  the	  60	  
envelope	   complex	   from	   immune	   recognition	   and	   inhibitor	   attack	   (8,	   12).	  Most	   of	   the	   gp120	  61	  
outer	  domain	   is	   functionally	  not	   important	   (7,	  13)	  and	  allows	  the	  virus	  to	  rapidly	  mutate	  and	  62	  
evade	   any	   envelope	   targeting	   agent	   (12).	   Antibody-­‐based	   vaccines	   and	   entry	   inhibitors	   thus	  63	  
need	  to	  act	  against	  a	  wide	  spectrum	  of	  genetically	  divergent	  HIV	  strains	  to	  be	  effective,	  ideally	  64	  
by	  targeting	  conserved,	  yet	  easily	  accessed	  sites	  on	  the	  viral	  envelope,	  which	  are	  important	  for	  65	  
the	   function	   of	   the	   envelope	   trimer	   and	   cannot	   be	   altered	   without	   significant	   fitness	   costs.	  66	  
Rare,	   broadly	   active	   and	   potent	   neutralizing	   antibodies	   can	   emerge	   in	   natural	   infection	   (14).	  67	  
Vaccine	  immunogens,	  however,	  capable	  of	  eliciting	  such	  responses,	  still	  need	  to	  be	  developed	  68	  
and,	   likewise,	   means	   to	   design	   and	   select	   inhibitors,	   which	   target	   conserved	   and	   accessible	  69	  
domains,	  still	  need	  to	  be	  created.	  	  70	  
Here	  we	  employed	  the	  Designed	  Ankyrin	  Repeat	  Protein	  (DARPin)	  technology	  (15-­‐19)	  to	  derive	  71	  
HIV	  envelope-­‐specific	  entry	  inhibitors.	  We	  have	  previously	  utilized	  the	  technology	  successfully	  72	  
	  4	  
	  
to	   develop	  DARPins	   specific	   for	   CD4,	  which	   proved	   to	   be	   highly	   potent	   in	   inhibiting	   entry	   of	  73	  
divergent	  HIV	   strains	   (18).	  DARPins,	   like	   the	  natural	   ankyrin	   repeat	  proteins	   they	  are	  derived	  74	  
from	   (20),	   have	   exceptional	   binding	   properties	   and	   recognize	   particularly	  well	   targets	  with	   a	  75	  
defined	   rigid	   surface,	   such	   as	   folded	   proteins.	   Although	   they	   share	   many	   properties	   with	  76	  
antibodies,	   most	   noteworthy	   their	   high	   target	   specificity	   and	   affinity,	   DARPins	   differ	   from	  77	  
antibodies	   in	  size,	   structure	  and	  preference	   for	   folded	  proteins	  as	   targets	   (19).	   In	   the	  current	  78	  
study	   we	   sought	   to	   explore	   whether	   these	   distinct	   properties	   of	   DARPins	   allow	   selection	   of	  79	  
binding	   molecules	   which	   recognize	   epitopes	   on	   gp120	   differing	   from	   those	   targeted	   by	  80	  
antibodies	  and,	  which	  upon	  binding	  to	  virions,	  interfere	  with	  HIV	  entry.	  81	  
To	   this	   end,	  we	  performed	   four	   independent	   series	   of	   ribosome	  display	   selections	   of	   gp120-­‐82	  
specific	  DARPins,	  utilizing	  different	  gp120	  molecules	  and	  epitope	  display	  approaches	  (Figure	  1A,	  83	  
B).	   Our	   selections	   yielded	   a	   variety	   of	   gp120-­‐directed	   DARPin	  molecules	  which	   all	   proved	   to	  84	  
depend	   to	  a	  higher	  degree	  on	  a	   structural	   conservation	  of	   the	  envelope	  protein	   than	  gp120-­‐85	  
specific	   antibodies	   recognizing	   overlapping	   domains.	   Most	   noteworthy,	   DARPin	   5m3_D12	  86	  
proved	   to	   recognize	   the	   V3	   loop	   in	   a	   highly	   conformation	   dependent	   manner.	   This	   clone	  87	  
recognized	  the	  V3	  loop	  on	  wild-­‐type	  gp120	  protein	  as	  well	  as	  in	  the	  context	  of	  the	  trimeric	  spike	  88	  
on	  virus	  particles	  and	  bound	  to	  structurally	  arrested	  V3	   loop	  mimetic	  peptides,	  but	  unlike	  V3	  89	  
loop	   antibodies,	   showed	   dramatically	   reduced	   capacity	   to	   bind	   to	   linear	   V3	   loop	   peptides.	  90	  
Importantly,	  V3	  loop	  antibodies	  largely	  fail	  to	  interact	  with	  the	  V3	  loop	  on	  envelope	  trimers	  in	  91	  
the	   presence	   of	   active	   V1V2	   shielding	   on	   tier	   2	   viruses	   and	   thus	   have	   in	   most	   cases	   only	  92	  
marginal	   or	   no	   neutralization	   activity	   (21).	   On	   the	   contrary,	   DARPin	   5m3_D12	   was	   in	   part	  93	  
capable	  of	  bypassing	  V1V2	  shielding	  of	  tier	  2	  HIV	  isolates,	  albeit	  in	  a	  strain-­‐dependent	  manner,	  94	  




Materials	  and	  Methods	  97	  
	  98	  
Reagents	  99	  
Reagents	  were	  kindly	  provided	  by	  following	  groups:	  soluble	  CD4	  (sCD4)	  by	  W.	  Olson	  (Progenics	  100	  
Pharmaceuticals	  Inc.,	  Tarrytown,	  New	  York,	  USA);	  mAbs	  IgG1b12	  (22),	  b6	  (23),	  PGT128	  (24)	  by	  101	  
D.	   Burton	   (The	   Scripps	   Research	   Institute,	   La	   Jolla,	   USA);	  mAb	   1-­‐79	   (25)	   by	  M.	   Nussenzweig	  102	  
(Rockefeller	  University,	  New	  Yor,	  NY);	  mAb	  2G12	  (26)	  by	  H.	  Katinger	  (Polymun,	  Vienna,	  Austria);	  103	  
mAbs	  17b,	  19b,	  48D,	  A32	  (27)	  by	  J.	  Robinson	  (Tulane	  University,	  USA);	  447-­‐52D	  (28)	  by	  S.	  Zolla	  104	  
Pazner	   and	   F425	   B4e8	   (29)	   by	   Dr.	   Marshall	   Posner	   and	   Dr.	   Lisa	   Cavacini	   via	   the	   NIH	   AIDS	  105	  
Research	   and	   Reference	   Reagent	   Program,	   Division	   of	   AIDS,	   NIAID,	   NIH.	   CD4M47	   was	  106	  
synthesized	  as	  described	  (30).	  Linear	  and	  cyclic	  V3	  mimetic	  peptides	  from	  strains	  JR-­‐FL	  and	  MN	  107	  
were	  synthesized	  as	  described	  (31).	  The	  following	  V3	  loop	  peptides	  were	  used	  (sequences	  are	  108	  
indicated	  in	  brackets).	  	  109	  
• Linear	   peptides:	   linear	   (JR-­‐FL)	   (NNTRKSIHIGPGRAFYTTGEIIG);	   linear	   (MN)	  110	  
(GGGGYNKRKRIHIGPGRAFYTTKNIIG).	  	  111	  
• Structural	  V3	  loop	  mimetics	  which	  were	  cyclized	  by	  a	  D-­‐Pro-­‐L-­‐Pro	  (DPP)	  dipeptide	  which	  112	  
stabilizes	   the	   hairpin	   conformation:	   cyclic	   IY	   (MN)	   (KRIHIGPGRAFYTTDPP);	   cyclic	   IY	  113	  
(MNmut)	   (KRIHIGAGRAFYTTDPP);	   cyclic	   IY	   (JR-­‐FL)	   (KSIHIGPGRAFYTTDPP);	   cyclic	   IF	   (MN)	  114	  
(KRIHIGPGRAFYTDPP);	   cyclic	   IF	   (JR-­‐FL)	   (TCKSIHIGPGRAFYTCGDPP)	  with	   the	   Cys	   residues	  115	  
disulfide	  bonded;	  cyclic	  HY	  (JR-­‐FL)	  (SIHIGPGRAFYTTDPP);	  cyclic	  HF	  (MN)	  (RIHIGPGRAFYT	  116	  
DPP);	   cyclic	  HF1	   (JR-­‐FL)	   (SIHIGPGRAFYTDPP);	   cyclic	  HF2	   (JR-­‐FL)	   (RCSIHIGPGRAFYTCGDPP)	  117	  
with	  the	  Cys	  residues	  disulfide	  bonded;	  cyclic	  HF3	  (JR-­‐FL)	  (RKSIHIGPGRAFYTTGDPP).	  118	  
• A	  cyclic	  peptide	  cyclized	  by	  a	  disulfide	  bond	  between	  the	  two	  cysteines:	  cyclic	  SS	  (JR-­‐FL)	  119	  
(GNCRKSIHIGPGRAFYTTGCG).	  	  120	  
For	   the	   peptide	   ELISA,	   biotinylated	   peptides	   were	   used.	   The	   linear	   (MN)	   peptide	   was	  121	  
biotinylated	  directly	  and	  the	  cyclic	  IY	  (MN)	  had	  a	  PEG08	  linker	  between	  the	  mimetic	  and	  biotin	  122	  
(see	  (31)).	  All	  synthetic	  peptides	  were	  ≥95%	  pure	  by	  analytical	  HPLC	  and	  gave	  electrospray	  MS	  123	  
spectra	  consistent	  with	  the	  expected	  masses.	  124	  
	  6	  
	  
Gp120	  proteins	  	  125	  
Codon-­‐optimized	  sequences	  of	  strain	  JR-­‐FL	  gp120	  wild	  type,	  gp120D368R,	  gp120I420R	  and	  the	  loop	  126	  
deletion	  mutants	  (32,	  33)	  were	  custom	  synthesized	  (GeneArt,	  Germany),	  fused	  to	  a	  C-­‐terminal	  127	  
AviTag	  and	  cloned	  into	  the	  expression	  vector	  CMV/R	  (34).	  Recombinant	  gp120	  was	  produced	  by	  128	  
transient	  transfection	  of	  HEK	  293T	  Freestyle	  suspension	  cells	  maintained	  in	  serum-­‐free	  medium	  129	  
as	   described	   by	   the	   manufacturer	   (Invitrogen,	   USA).	   Gp120	   was	   purified	   from	   culture	  130	  
supernatants	   using	   Galantus	   nivalis	   lectin	   resin	   (Vector	   Laboratories)	   as	   described	   (35).	  131	  
Retrieved	  gp120	  was	  mono-­‐biotinylated	  using	  BirA	  as	  described	  by	   the	  manufacturer	   (Roche)	  132	  
followed	   by	   Superdex200	   size	   exclusion	   chromatography	   (GE	   Healthcare,	   USA)	   to	   derive	  133	  
monomeric	  gp120.	  To	  obtain	  deglycosylated	  gp120,	  500	  μg	  of	  gp120	  were	  subjected	  to	  0.15	  U	  134	  
α(1-­‐2,3,6)-­‐mannosidase	  (from	  jack	  bean;	  Europa	  Bioproducts)	  for	  30	  h	  at	  37°C	  in	  the	  presence	  135	  
of	   protease	   inhibitors	   (Complete	   Mini	   EDTA-­‐free	   Protease	   Inhibitor	   Cocktail	   Tablets,	   Roche	  136	  
Applied	   Science,	   Switzerland).	   The	   gp120ΔV1V2	   construct	   was	   created	   as	   previously	   described	  137	  
(21).	  The	  ΔV1	  and	  ΔV3	  gp120	  loop	  deletions	  were	  created	  with	  the	  following	  linker	  sequences	  138	  
for	   deleted	   loops	   (HXB2	   numbering)	   ΔV1	   linker:	   C131KDVNAGEIKNC157;	   ΔV3	   linker:	  139	  
C296TGAGHC331	  .	  140	  
	  141	  
DARPin	  selection	  by	  ribosome	  display	  142	  
Selection	  with	   the	  N2C	  and	  N3C	  DARPin	   libraries	  was	  performed	  essentially	  as	  described	   (36-­‐143	  
38).	  During	   ribosome	  display,	   a	   library	  of	  DARPins	   is	   translated	   in	   vitro	  without	   stop	   codons,	  144	  
such	  that	  a	  ternary	  complex	  of	  ribosome,	  mRNA	  and	  the	  still	  attached,	  newly	  translated	  DARPin	  145	  
is	   formed.	   Thereby,	   the	   genotype	   is	   coupled	   to	   the	   phenotype,	   allowing	   the	   enrichment	   of	  146	  
DARPins	  which	  specifically	  bind	  to	  the	  respective	  target	  (Figure	  1A).	  After	  each	  selection	  round	  147	  
RNA	  of	   bound	  DARPin	   species	   is	   amplified	   by	   RT-­‐PCR.	   The	   obtained	   cDNA	   constitutes	   a	   sub-­‐148	  
library	  of	  the	  starting	  library.	  	  Selection	  in	  absence	  of	  target	  protein	  is	  performed	  in	  parallel	  to	  149	  
monitor	  the	  extent	  of	  background	  (off-­‐target)	  cDNA	  amplification.	  Comparisons	  of	  the	  quantity	  150	  
of	  amplified	  RT-­‐PCR	  products	  from	  target	  and	  background	  selection	  indicate	  when	  enrichment	  151	  
of	  target-­‐specific	  DARPins	  occurs	  (38).	  Commonly,	  several	  consecutive	  rounds	  (>3)	  of	  selection	  152	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are	   necessary	   to	   derive	   sub-­‐libraries	   which	   are	   highly	   enriched	   for	   target-­‐specific	   DARPins.	  153	  
During	  this	  process,	  a	  balance	  between	  maintaining	  diversity	  in	  the	  library	  (in	  order	  not	  to	  lose	  154	  
specific	  binders	  with	  low	  affinity	  too	  early),	  and	  stringency	  of	  panning	  (to	  deselect	  nonspecific	  155	  
binders)	  has	  to	  be	  achieved	  (37).	  Stringency	  can	  be	  modulated	  by	  the	  intensity	  of	  the	  washing	  156	  
steps,	   tuning	  of	  RT-­‐PCR	  cycles	  or	  depletion	  of	   low-­‐affinity	  binders	  by	  addition	  of	  excess,	  non-­‐157	  
immobilized	  target	  (off-­‐rate	  selection,	  see	  below).	  Prior	  to	  the	  experiments	  described	  here	  we	  158	  
performed	  a	  series	  of	  analyses	  to	  probe	  which	  selection	  conditions	  prove	  best	  for	  our	  different	  159	  
targets	  (data	  not	  shown).	  	  160	  
In	  summary,	  we	  found	  that	  in	  order	  to	  achieve	  selection	  of	  gp120-­‐specific	  binders,	  adding	  the	  161	  
target	   in	   solution	   rather	   than	   immobilized	   on	   a	   surface	  was	   key,	   as	   previously	   described	   for	  162	  
other	  targets	  (38).	  Biotinylated	  gp120	  was	  bound	  to	  streptavidin-­‐coupled	  magnetic	  microbeads	  163	  
(MyOne-­‐T1	   Dynabeads,	   Invitrogen,	   USA)	   and	   panning	   was	   performed	   in	   microtubes.	   Early	  164	  
rounds	  of	  selection	  (1-­‐3)	  were	  kept	  at	  low	  stringency	  with	  typically	  3-­‐5	  short	  washing	  steps	  (5	  165	  
min),	  while	  intensity	  of	  washing	  was	  increased	  during	  subsequent	  rounds	  of	  selection	  (typically	  166	  
8-­‐10	  wash	   steps	   of	   10	  min	   each).	   The	  most	   important	   adaptation	   to	   the	   standard	   ribosome	  167	  
display	  protocol	  previously	  described	  (18,	  36,	  37)	  was	  the	  omission	  of	  heparin	   in	  the	  panning	  168	  
buffer.	  Heparin	  is	  usually	  added	  during	  panning	  to	  prevent	  non-­‐specific	  RNA	  binding	  to	  protein	  169	  
or	  surfaces.	  Since	  gp120	  has	  been	  described	  to	  have	  multiple	  heparin	  binding	  sites	  (39)	  and	  in	  170	  
vitro	   efficiently	   interacts	   with	   heparin	   (40),	   addition	   of	   heparin	   during	   the	   selection	   process	  171	  
could	   block	   otherwise	   accessible	   sites	   on	   gp120.	   Indeed,	   we	   found	   that	   addition	   of	   heparin	  172	  
completely	  obliterated	  gp120-­‐specific	  DARPin	  selections	  (data	  not	  shown).	  Thus,	  while	  omission	  173	  
of	  heparin	  can	  lead,	  to	  some	  extent,	  to	  false	  positive	  binder	  enrichment	  as	  judged	  by	  RT-­‐PCR,	  174	  
selections	  of	  DARPins	   in	   the	   absence	  of	   heparin	   proved	   the	  only	   possible	   approach	   to	   select	  175	  
gp120-­‐specific	  DARPins	  (data	  not	  shown).	  	  176	  
The	  number	  of	  selection	  rounds	  performed	  in	  each	  respective	  selection	  is	  stated	  in	  Figure	  1B.	  177	  
Sub-­‐libraries	   for	  which	  a	  target-­‐specific	  enrichment	  by	  RT-­‐PCR	  was	  evident	  were	  screened	  for	  178	  
DARPin	  molecules	  that	  specifically	  bind	  to	  gp120	  by	  ELISA	  (see	  below).	  In	  an	  alternate	  screening	  179	  
approach	  N3C	  sub-­‐libraries	  from	  Selection	  II,	  which	  yielded	  1st	  and	  2nd	  generation	  binders	  based	  180	  
on	   ELISA	   gp120,	   were	   re-­‐probed	   and	   tested	   directly	   for	   inhibition	   of	   HIV	   by	   pseudovirus	  181	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inhibition	  screening	  against	  strains	  JR-­‐FL,	  JR-­‐FL∆V1V2,	  NL4-­‐3,	  SHIV	  SF162	  P3	  and	  MuLV	  on	  TZM-­‐182	  
bl	  cells	  (see	  below).	  	  183	  
	  184	  
Detection	  of	  DARPin	  and	  mAb	  binding	  to	  target	  protein	  and	  peptides	  by	  ELISA	  185	  
20	   nM	   biotinylated	   gp120	   or	   peptide	   was	   immobilized	   to	   white	   high	   binding	   microplates	  186	  
(Costar)	  that	  had	  been	  coated	  with	  60	  nM	  Neutravidin	  (Pierce)	  either	  over-­‐night	  at	  4°C	  or	  for	  1	  187	  
h	   at	   37°C,	   followed	   by	   three	   wash	   steps	   with	   TBST	   (Tris	   buffered	   saline	   containing	   0.1%	  188	  
Tween	  20),	  pH	  7.5.	  189	  
Gp120	  proteins	  were	  either	  probed	  unliganded	  or	  triggered	  with	  50	  nM	  sCD4	  or	  CD4M47.	  Serial	  190	  
dilutions	  of	  either	  purified	  DARPins	  or	  crude	  extract	  from	  DARPin-­‐producing	  E.	  coli	  were	  added	  191	  
in	  TBSTB	  (TBST	  with	  0.5%	  bovine	  serum	  albumin),	  pH	  7.5.	  Unbound	  material	  was	  washed	  off	  in	  192	  
TBST	   and	   bound	   DARPins	   were	   detected	   via	   their	   His-­‐tag	   using	   a	   mouse	   anti-­‐193	  
polyHistidine−alkaline	  phosphatase	   antibody	   (clone	  HIS-­‐1;	   Sigma-­‐Aldrich)	   and	  Tropix	   CDP-­‐star	  194	  
chemiluminescent	   substrate	   (Applied	  Biosystems).	  MAbs	  were	   detected	  with	   polyclonal	   Anti-­‐195	  
Human	   IgG	   (Fc	   specific)−Alkaline	   Phosphatase	   antibody	   produced	   in	   goat	   (Sigma-­‐Aldrich).	  196	  
Emission	   of	   relative	   light	   units	   was	   detected	   on	   a	   Dynex	   Technologies	   Luminometer.	   For	  197	  
competition	  ELISA,	  gp120	  was	  pretreated	  with	  33	  nM	  of	  the	  respective	  mAb	  or	  sCD4	  and	  the	  198	  
subsequent	  ELISA	  steps	  were	  performed	  as	  described	  above.	  The	  percentages	  of	  binding	  in	  the	  199	  
presence	   of	   competitor	   were	   determined	   at	   saturating	   DARPin	   concentrations.	   For	   peptide	  200	  
competition	  ELISA,	  the	  DARPin	  5m3_D12	  or	  mAbs	  447-­‐52D	  and	  F425-­‐4e8	  were	  pretreated	  with	  201	  
indicated	   concentrations	   of	   peptide	   and	   the	   subsequent	   ELISA	   steps	   were	   performed	   as	  202	  
described	  above.	  203	  
	  204	  
Affinity	   maturation	   of	   DARPin	   binders	   by	   diversification	   by	   error-­‐prone	   PCR	   and	   off-­‐rate	  205	  
selection	  	  206	  
Sub-­‐libraries	   of	   interest	   were	   randomized	   by	   amplification	   via	   error-­‐prone	   PCR	   (41),	   using	   a	  207	  
dNTP-­‐Mutagenesis	  Kit	  (Jena	  Biosciences)	  including	  50	  µM	  of	  each	  of	  the	  nucleotide	  analogs	  8-­‐208	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oxo-­‐dGTP	   and	   dPTP	   in	   the	   RT-­‐PCR	   reaction	   of	   ribosome	   display.	   For	   the	   following	   panning	  209	  
round	  a	  one-­‐to-­‐one	  mix	  of	   error-­‐prone	  and	  original	   PCR	  product	  was	  used	   as	   a	   template	   for	  210	  
RNA	  transcription.	  211	  
To	  select	  clones	  with	  improved	  affinity,	  DARPin-­‐ribosome	  complexes	  were	  first	  allowed	  to	  bind	  212	  
to	  bead-­‐immobilized	  target	  before	  an	  100	  to	  300-­‐fold	  molar	  excess	  of	  non-­‐biotinylated	  gp120	  213	  
was	   added	   as	   competitor	   for	   1-­‐2	   h,	   followed	   by	   10-­‐15	   times	   10	  min	  washing	   steps.	   DARPin	  214	  
binders	  with	  a	  fast	  off-­‐rate	  are	  captured	  by	  the	  non-­‐biotinylated	  competitor	  target	  in	  solution	  215	  
and	  will	  be	  lost	  during	  subsequent	  washing	  steps.	  In	  contrast,	  high-­‐affinity	  binders	  with	  a	  slow	  216	  
off-­‐rate	   remain	   bound	   to	   bead-­‐coupled	   target	   protein	   and	   their	   mRNA	   will	   eventually	   be	  217	  
preferentially	   eluted	   and	   amplified.	   This	   off-­‐rate	   selection	  was	   then	   followed	   by	   a	   ribosome	  218	  
display	  round	  in	  the	  absence	  of	  competitor	  and	  subsequent	  washing	  for	  10	  times	  5	  min,	  to	  re-­‐219	  
enrich	  for	  specific	  binders,	  since	  the	  proportion	  of	  specific	  binders	  is	  lowered	  in	  resulting	  sub-­‐220	  
libraries	  by	  the	  off-­‐rate	  selection	  step	  (42).	  Afterwards,	  individual	  clones	  from	  the	  sub-­‐libraries	  221	  
were	  screened	  by	  binding	  ELISA	  as	  described	  above.	  	  222	  
	  223	  
Molecular	  phylogenetic	  analysis	  by	  the	  Maximum	  Likelihood	  method	  	  224	  
Phylogenetic	  analyses	  were	  conducted	   in	  MEGA5	  (43)	  using	  the	  Maximum	  Likelihood	  method	  225	  
based	  on	  the	  JTT	  matrix-­‐based	  model	  (44).	  The	  trees	  with	  the	  highest	  log	  likelihood	  are	  shown.	  226	  
Initial	  tree(s)	  for	  the	  heuristic	  search	  were	  obtained	  automatically	  employing	  the	  BIONJ	  method	  227	  
with	  MCL	  distance	  matrix.	  	  228	  
	  229	  
DARPin	  purification	  and	  analysis	  230	  
DARPins	  were	  produced	  in	  E.	  coli	  XL10	  Gold	  strain	  via	  the	  qQE30	  system	  with	  Isopropyl	  β-­‐D-­‐1-­‐231	  
thiogalactopyranoside	   (IPTG)	   induction	   and	   purified	   using	  Ni-­‐NTA	   affinity	   chromatography	   as	  232	  
described	   (45).	   Obtained	   DARPin	   proteins	   were	   checked	   by	   SEC-­‐MALS	   (Size	   Exclusion	  233	  
Chromatography	   coupled	   to	  Multi	   Angle	   Light	   Scattering)	   for	   oligomerization	   state.	   DARPins	  234	  
that	   exhibited	   a	   tendency	   to	   form	   dimers	   or	   higher	   order	   aggregates	   were	   excluded	   from	  235	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further	   analysis.	   For	   direct	   neutralization	   screening,	   small	   scale	   DARPin	   preparations	   were	  236	  
purified	  from	  400	  µl	  bacterial	  lysate	  in	  96-­‐well	  plates	  using	  Ni-­‐NTA-­‐coated	  magnetic	  beads	  (His	  237	  
Mag	  Sepharose	  Ni;	  GE	  Healthcare,	  USA).	  	  238	  
	  239	  
Virus	  preparation	  240	  
Env-­‐pseudotyped	   viruses	   were	   prepared	   by	   cotransfection	   of	   HEK	   293-­‐T	   cells	   with	   plasmids	  241	  
encoding	   the	   respective	   Env	   genes	   and	   the	   luciferase	   reporter	   HIV	   vector	   pNLluc-­‐AM	   as	  242	  
described	   previously	   (46).	   The	   following	   envelope	   genes	   were	   used:	   NL4-­‐3	   (47),	   JR-­‐FL	   (48),	  243	  
SF162-­‐LS	   (49),	   NAB1pre-­‐cl39x,	   NAB2pre-­‐cl_3,	   NAB3pre-­‐cl_43,	   NAB4pre-­‐cl_1,	   NAB05.1,	  244	  
NAB10pre-­‐cl_2	   and	   NAB12pre-­‐cl_7	   (50),	   ZA110.C.10.14	   and	   V1V2-­‐deleted	   envs	   (21).	  245	  
ZA110.C.10.14	  (21)	  was	  isolated	  in	  the	  frame	  of	  the	  Zurich	  Primary	  HIV	  Infection	  Study	  (ZPHI),	  246	  
Division	   of	   Infectious	   Diseases	   and	   Hospital	   Epidemiology	   supported	   by	   the	   University	   of	  247	  
Zurich’s	  Clinical	  research	  Priority	  Program	  (CRPP).	  	  248	  
The	   panel	   of	   reference	   subtype	   B	   env	   clones	   comprising	   the	   following	   envelopes,	   6535.3,	  249	  
AC10.0.29,	   CAAN5342.A2,	   PVO.4,	   QH0692.42,	   REJO4541.67,	   RHPA4259.7,	   SC422661.8,	  250	  
THRO4156.18,	   TRO.11	   and	  WITO4160.33	   (51)	   was	   obtained	   through	   the	   AIDS	   Research	   and	  251	  
Reference	  Reagent	  Program,	  Division	  of	  AIDS,	  NIAID,	  NIH.	  252	  
	  253	  
Neutralization	  assay	  using	  Env-­‐pseudotyped	  virus	  254	  
The	   neutralization	   activity	   of	  DARPins	   and	  mAbs	  was	   evaluated	   on	   TZM-­‐bl	   cells	   as	   described	  255	  
previously	  (46).	  Virus	  input	  was	  chosen	  to	  yield	  virus	  infectivity	  corresponding	  to	  5,000–20,000	  256	  
RLU	  (relative	  light	  units)	  in	  the	  absence	  of	  inhibitors.	  The	  antibody	  concentrations	  or	  reciprocal	  257	  
plasma	   titers	   causing	   50%	   reduction	   in	   viral	   infectivity	   (inhibitory	   concentration	   IC50	   or	  258	  
neutralization	  titer	  NT50)	  were	  calculated	  by	  fitting	  pooled	  data	  from	  two	  to	  three	  independent	  259	  
experiments	  to	  sigmoid	  dose–response	  curves	  (variable	  slope)	  using	  Prism	  software	  (GraphPad	  260	  
Software).	   If	   50%	   inhibition	   was	   not	   achieved	   at	   the	   highest	   or	   lowest	   drug	   or	   plasma	  261	  
concentration,	  a	  greater	  than	  or	  less	  than	  value	  was	  recorded.	  262	  
	  11	  
	  
For	   competition	   inhibition	   assays	  with	   V3-­‐petides,	  mAb	   and	   DARPin	   inhibitor	   concentrations	  263	  
were	  chosen	  that	   inhibit	   the	  env-­‐pseudotyped	  viruses	   to	  95%.	  The	  respective	   inhibitor	  at	   the	  264	  
fixed	  dose	  and	  increasing	  serial	  dilutions	  of	  the	  different	  V3-­‐petides	  were	  preincubated	  for	  1	  h,	  265	  
then	  virus	  was	  added	  and	   the	  entire	  mixture	   incubated	   for	  an	  additional	  hour	  before	  TZM-­‐bl	  266	  
cells	  were	   added.	   Infection	  was	  measured	   after	   48	   h	   as	   described	   (46).	   Percent	   inhibition	   of	  267	  
DARPin	  and	  mAb	  in	  presence	  of	  competing	  peptide	  was	  calculated	  in	  relation	  to	  control	  wells	  268	  




Selection	  of	  gp120	  specific	  DARPin	  molecules	  273	  
The	  high	  structural	  flexibility	  of	  the	  surface	  unit	  gp120	  within	  the	  viral	  envelope	  trimer	  and	  its	  274	  
extensive	   glycosylation	   are	   considered	   major	   barriers	   for	   the	   selection	   of	   neutralizing	  275	  
antibodies,	  both	  in	  natural	  infection	  and	  upon	  vaccination	  (8,	  10,	  52).	  In	  Selection	  I	  (Figure	  1B)	  276	  
we	  sought	  to	  define	  whether	  DARPins	  can	  overcome	  these	  barriers	  and	  efficiently	  bind	  to	  this	  277	  
flexible,	   highly	   glycosylated	   target.	   DARPin	  DNA	   libraries	   encoding	   either	   two	   (N2C)	   or	   three	  278	  
(N3C)	   internal	  randomized	  ankyrin	  repeats	  between	  an	  N-­‐	  and	  C-­‐terminal	  capping	  repeat	  (15)	  279	  
were	   subjected	   to	   ribosome	   display	   selections	   and	   panned	   against	   recombinant	   gp120	   from	  280	  
strain	   JR-­‐FL	   (Figure	  1B).	  Enrichment	  of	   specific	  binders	   in	  both	   the	  N2C	  and	   the	  N3C	   libraries	  281	  
was	   observed	   based	   on	   RT-­‐PCR	   products	   after	   four	   rounds	   of	   ribosome	   display	   (data	   not	  282	  
shown).	  285	  individual	  clones	  of	  each	  library	  were	  expressed	  in	  Escherichia	  coli,	  crude	  extracts	  283	  
screened	   for	  gp120	  binding	  by	  ELISA	  and	   reactive	  clones	  sequenced.	  None	  of	   the	  N2C	  clones	  284	  
and	  only	  one	  single	  clone	   from	  the	  N3C	   library	  proved	  to	  encode	  a	  DARPin	  which	  specifically	  285	  
bound	  to	  JR-­‐FL	  gp120	  (Figure	  1B),	  indicating	  that	  DARPins	  have	  a	  limited	  capacity	  in	  recognizing	  286	  




DARPin	   panning	   on	   gp120	   target	   proteins	   with	   decreased	   flexibility	   and	   degree	   of	  289	  
glycosylation	  290	  
This	   low	   frequency	   in	   selecting	   gp120-­‐specific	   DARPin	   binders	   prompted	   us	   to	   probe	   three	  291	  
alternative	   selection	   strategies	   to	   determine	  whether	  modified	   gp120	   proteins	  with	   reduced	  292	  
structural	  flexibility	  or	  decreased	  camouflage	  by	  glycosylation	  prove	  better	  selection	  targets.	  In	  293	  
a	  first	  approach	  we	  limited	  the	  structural	  flexibility	  of	  gp120	  by	  ligation	  with	  the	  CD4	  mimetic	  294	  
mini-­‐protein	   CD4M47,	   which	   arrests	   gp120	   in	   the	   CD4-­‐bound	   conformation	   (30)	   (Figure	   1B,	  295	  
Selection	  II).	  In	  a	  further	  strategy,	  we	  probed	  whether	  removal	  of	  the	  V1V2	  domain,	  the	  largest	  296	  
and	  most	  flexible	  of	  the	  gp120	  variable	  loop	  domains	  (53,	  54),	  improves	  the	  efficiency	  of	  gp120-­‐297	  
specific	   DARPin	   selection	   (gp120ΔV1V2,	   Selection	   III).	   Additionally,	   we	   explored	   whether	   de-­‐298	  
glycosylated	  gp120	  allows	  selection	  of	  gp120-­‐specific	  DARPins	  at	  higher	   frequency	  (Figure	  1B,	  299	  
Selection	   IV)	   as	   sites	   vulnerable	   to	   neutralizing	   antibody	   attack	   are	   known	   to	   be	   efficiently	  300	  
shielded	  by	  the	  Env	  protein's	  heavy	  glycosylation	  (9-­‐11).	  	  301	  
After	  three	  to	  five	  rounds	  of	  ribosome	  display,	  95	  clones	  from	  each	  sub-­‐library	  were	  screened	  302	  
by	   ELISA	   for	   reactivity	   with	   the	   respective	   target	   protein	   used	   during	   panning.	   Gp120	  303	  
conformationally	  arrested	  by	  ligation	  with	  the	  CD4	  mimetic	  proved	  the	  most	  effective	  target	  as	  304	  
already	  after	   three	   rounds	  of	   selection,	  we	  derived	   two	  specific	  binders	   from	  the	  N2C	   library	  305	  
and	   nine	   specific	   binders	   from	   the	   N3C	   library	   of	   Selection	   II.	   In	   Selection	   III	   (target:	  306	  
gp120ΔV1V2)	   and	   Selection	   IV	   (target:	   deglycosylated	   gp120)	   the	   derived	  N2C	   and	  N3C	   sub-­‐307	  
libraries	  yielded	  no	  gp120-­‐specific	  clones.	  Although	  a	  few	  N2C	  clones	  (3	  clones	   in	  Selection	   III	  308	  
and	  1	  clone	  in	  Selection	  IV)	  with	  low	  reactivity	  with	  gp120	  were	  detected,	  these	  had,	  however,	  309	  
too	  low	  affinity	  (>10µM)	  for	  gp120	  to	  allow	  further	  follow-­‐up	  analysis	  (data	  not	  shown).	  310	  
	  311	  
Affinity	  maturation	  of	  gp120-­‐specific	  DARPins	  312	  
Our	  primary	   screen	  of	   sub-­‐libraries	   from	   the	   four	   independent	   selection	   strategies	   yielded	   in	  313	  
total	   12	  gp120-­‐specific	   clones	   (referred	   to	  as	  1st	   generation	  binders,	   Figure	  1B	  and	  Figure	  2),	  314	  
which	   all	   originated	   from	  Selections	   I	   and	   II.	  Of	   note,	   specific	   binding	  of	   these	  1st	   generation	  315	  
binders	  in	  ELISA	  to	  the	  respective	  gp120	  target	  protein	  used	  in	  the	  selection	  was	  only	  detected	  316	  
	  13	  
	  
at	  high	  nanomolar	  to	  micromolar	  concentrations,	  indicative	  of	  relatively	  low	  affinities	  of	  these	  317	  
DARPins	  for	  gp120	  (Figure	  3	  and	  data	  not	  shown).	  In	  order	  to	  select	  for	  gp120-­‐specific	  DARPins	  318	  
with	   improved	   affinities,	   the	   sub-­‐libraries	   of	   all	   four	   selection	   strategies	   were	   subjected	   to	  319	  
additional	  selection	  rounds	  with	  the	  aim	  to	  diversify	  specific	  binders	  and	  to	  specifically	  select	  320	  
for	  high-­‐affinity	  binders	  using	  off-­‐rate	  selection.	  Clones	  obtained	  after	  this	  affinity	  maturation	  321	  
step	  are	   referred	   to	  as	   “2nd	   generation	  binders”	   (Figure	  1B	  and	  Figure	  2).	  Overall	   the	  affinity	  322	  
maturation	   and	   off-­‐rate	   selection	   step	   proved	   successful.	   Selection	   I	   yielded	   four	   improved	  323	  
derivatives	  of	  the	  N3C	  clone	  4a3_H3,	  selected	   in	  the	  primary	  screen,	  and	  four	  additional	  N2C	  324	  
binders	  whereas	  Selection	  II	  yielded	  5	  further	  N3C	  clones	  upon	  affinity	  maturation.	  	  325	  
For	  Selections	  III	  and	  IV,	  which	  only	  yielded	  particularly	  weak	  binders	  in	  the	  1st	  generation,	  we	  326	  
retrieved	  several	  2nd	  generation	  binders	  with	  improved	  reactivity	  for	  the	  respective	  target	  (13	  327	  
N2C	  from	  Selection	  III	  and	  10	  N2C	  binders	  from	  Selection	  IV;	  Figure	  1B).	  	  328	  
	   	  329	  
Characterization	  of	  gp120-­‐specific	  1st	  and	  2nd	  generation	  DARPins	  330	  
Sequence	  analysis	  of	  gp120-­‐specific	  DARPins	  obtained	  in	  the	  1st	  and	  2nd	  generation	  of	  selections	  331	  
revealed	   that	   individual	   clones	   derived	   from	   the	   same	  N2C	   or	   N3C	   sub-­‐library	  were	   in	  most	  332	  
cases	  highly	  related	  (Figure	  2	  and	  Supplement	  Figure	  S1).	  Based	  on	  the	  sequence	  analysis	  and	  333	  
binding	  efficacy	  in	  the	  initial	  screen,	  distinct	  clones	  from	  all	  selections	  were	  chosen	  for	  detailed	  334	  
binding	   and	   inhibitory	   activity	   analysis.	   To	   this	   end,	   DARPin	   preparations	   were	   purified	   and	  335	  
checked	  by	  SEC-­‐MALS	   for	  oligomeric	   state.	  DARPins	  which	  had	  a	   tendency	   to	   form	  dimers	  or	  336	  
higher	   order	   aggregates	   were	   excluded	   from	   further	   analysis	   (data	   not	   shown).	   The	   10	   N2C	  337	  
DARPin	  clones	  from	  Selection	  IV	  only	  differed	  in	  a	  few	  amino	  acids	  (Figure	  2).	  Unfortunately,	  all	  338	  
clones	  needed	   to	  be	  excluded	   from	   follow	  up	  as	   they	   formed	  higher	  order	  oligomers.	   For	  all	  339	  
other	   clones	   from	   Selection	   I,	   II	   and	   III	   selected	   for	   follow-­‐up,	   binding	   properties	   of	   purified	  340	  
DARPins	   to	   (i)	   full	   length,	   wild-­‐type	   (wt)	   gp120	   of	   strain	   JR-­‐FL,	   (ii)	   JR-­‐FL	   gp120	   liganded	   to	  341	  
CD4M47,	  (iii)	  JR-­‐FL	  gp120	  liganded	  to	  soluble	  CD4,	  and	  (iv)	  V1V2-­‐loop-­‐deleted	  JR-­‐FL	  gp120	  were	  342	  
determined.	   Figure	   3	   depicts	   gp120	   binding	   data	   for	   representative	   clones	   of	   each	   selection	  343	  
	  14	  
	  
series.	  In	  general,	  the	  derived	  DARPin	  clones	  portrayed	  gp120-­‐binding	  patterns	  that	  were	  in	  line	  344	  
with	  their	  respective	  selection	  strategy.	  	  345	  
Selection	  I	  346	  
Clones	   derived	   from	   the	  N2C	   and	  N3C	   sub-­‐libraries	   of	   Selection	   I	   were	   in	   both	   cases	   closely	  347	  
related	   (Figure	  2).	  While	  both	  N2C	  and	  N3C	  DARPins	  bound	  wt	  gp120	  efficiently,	   this	  binding	  348	  
was	  abolished	  in	  the	  presence	  of	  sCD4,	  but	  remained	  comparable	  to	  wt	  gp120	  when	  gp120	  was	  349	  
complexed	   with	   CD4M47	   (Figure	   3).	   	   Of	   note,	   the	   N2C	   clone	   6a2_A1	   bound	   V1V2-­‐deleted	  350	  
gp120	   efficiently,	   while	   the	   N3C	   clone	  H3_1B3	   failed	   to	   do	   so,	   indicating	   that	   these	   clones	  351	  
recognize	  distinct	  epitopes.	  	  352	  
	  353	  
Selection	  II	  	  354	  
Selection	   II	   (CD4M47-­‐liganded	   gp120)	   yielded	   clones	   with	   substantially	   divergent	   sequences	  355	  
and	   binding	   reactivities	   within	   the	   N3C	   sub-­‐library	   (Figure	   2).	   CD4	   ligation	   proved	   to	   be	   a	  356	  
decisive	  determinant	  for	  DARPin	  binding	  to	  gp120	  amongst	  Selection	  II	  clones	  (Figure	  3).	  None	  357	  
of	  the	  probed	  1st	  generation	  clones	  bound	  unliganded,	  wild-­‐type	  gp120:	  All	  N3C	  clones	  bound	  358	  
to	   CD4M47-­‐liganded	   gp120	   but	   not	   to	   CD4M47	   alone	   (Figure	   2	   and	   data	   not	   shown).	   In	  359	  
contrast,	  the	  N2C	  binder	  3m2_A12	  only	  bound	  to	  sCD4-­‐liganded	  gp120	  but	  none	  of	  the	  other	  360	  
probed	  targets,	  even	  though	  this	  binder	  was	  selected	  against	  CD4M47-­‐liganded	  gp120.	  The	  2nd	  361	  
generation	   clone	   5m3_D12	   was	   the	   only	   Selection	   II	   DARPin	   which	   recognized	   non-­‐CD4-­‐362	  
triggered	  wild-­‐type	  gp120,	  albeit	  with	  markedly	  lower	  efficacy	  than	  when	  triggered	  with	  either	  363	  
sCD4	  or	  CD4M47.	  In	  addition	  5m3_D12	  bound	  V1V2	  deleted	  gp120	  with	  high	  affinity.	  	  364	  
	  365	  
Selection	  III	  	  366	  
Despite	  relatively	  high	  sequence	  diversity	  amongst	  the	  13	  N2C	  clones	  obtained	  from	  Selection	  367	  
III,	   the	   probed	   clones	   displayed	   largely	   overlapping	   binding	   patterns	   (Figure	   3	   and	   data	   not	  368	  
shown).	   Two	   N2C	   clones,	   AKNF1_10	   and	   AKNF1_14,	   were	   selected	   for	   further	   analysis.	   In	  369	  
accordance	   with	   their	   selection	   against	   V1V2-­‐deleted	   gp120	   this	   envelope	   mutant	   was	  370	  
	  15	  
	  
recognized	  with	  highest	  efficiency	  but	  the	  clones	  also	  proved	  to	  recognize	  wild-­‐type	  gp120.	  CD4	  371	  
ligation	  again	  had	  a	  differential	  effect	  on	  the	  binding	  capacity	  of	  these	  clones.	  While	  CD4M47	  372	  
ligation	  had	  no	  influence,	  sCD4	  abolished	  the	  capacity	  of	  these	  DARPins	  to	  interact	  with	  gp120	  373	  
(Figure	  3).	  	  374	  
	  375	  
Defining	  binding	  domains	  of	  gp120-­‐specific	  DARPins	  	  	  	  376	  
In	  order	  to	  map	  the	  binding	  sites	  recognized	  by	  the	  gp120-­‐specific	  DARPins	  in	  more	  detail	  we	  377	  
studied	   the	   capacity	   of	   representative	   members	   of	   each	   selection	   to	   bind	   to	   a	   panel	   of	  378	  
recombinant	  JR-­‐FL	  gp120	  proteins	  which	   included	  (i)	   full	   length	  wild-­‐type	  protein,	   (ii)	   the	  CD4	  379	  
binding	   site	   (CD4bs)	  mutant	  gp120D368R	  known	   to	  obliterate	  CD4	  and	  CD4bs	  antibody	  binding	  380	  
(55-­‐57),	  (iii)	  the	  coreceptor	  binding	  site	  mutant	  (CoR-­‐bs)	  mutant	  gp120I420R	  known	  to	  eliminate	  381	  
binding	   of	   antibodies	   recognizing	   the	   CD4-­‐induced	   (CD4i)	   coreceptor	   binding	   site	   (27,	   58)	   as	  382	  
well	  as	  mutant	  gp120	  proteins	  lacking,	  (iv)	  the	  V1	  loop	  (gp120ΔV1),	  (v)	  the	  entire	  V1V2	  domain	  383	  
(gp120ΔV1V2),	  and	  (vi)	  the	  V3	  loop	  (gp120ΔV3)	  (Figure	  4).	  Functionality	  of	  all	  gp120	  proteins	  used	  384	  
in	  these	  studies	  was	  verified	  by	  assessing	  binding	  of	  gp120-­‐specific	  antibodies	  and	  CD4	  (Figure	  385	  
4A).	   The	   observed	   binding	   patterns	   of	   the	   mAbs	   were	   in	   accordance	   with	   the	   respective	  386	  
epitopes	  of	   the	  antibodies	  with	  CD4bs-­‐specific	  mAb	  b12	  and	  CD4IgG2	   lacking	   the	   capacity	   to	  387	  
bind	  the	  gp120D368R	  mutant	  protein,	  the	  V3-­‐loop-­‐specific	  mAbs	  failing	  to	  bind	  gp120ΔV3	  and	  the	  388	  
CD4i	   mAbs	   17b	   and	   48d	   portraying	   enhanced	   capacity	   to	   bind	   gp120ΔV1V2	   in	   the	   non-­‐CD4-­‐389	  
triggered	   conformation.	   Likewise,	   binding	   of	   CD4i	   mAbs	   to	   gp120I420R	   was	   obliterated	   and	  390	  
strongly	  reduced	  for	  gp120ΔV3,	  in	  line	  with	  the	  known	  contribution	  of	  the	  V3	  loop	  and	  bridging	  391	  
sheet	  to	  the	  binding	  domain	  of	  these	  antibodies	  (27,	  58,	  59).	  	  392	  
With	   the	   exception	   of	   DARPins	   from	   Selection	   II,	   which	  were	   selected	   against	   CD4-­‐triggered	  393	  
gp120	   and	   which	   require	   this	   conformation	   for	   effective	   binding,	   all	   other	   DARPins	   bound	  394	  
efficiently	  to	  the	  CD4bs	  mutant	  gp120D368R	  (Figure	  4B).	  Most	  strikingly,	  only	  Selection	  II	  DARPin	  395	  
5m3_D12	  bound	  the	  CoR-­‐bs	  mutant	  gp120I420R,	  indicating	  that	  the	  structural	  arrest	  inferred	  by	  396	  
this	  mutant	  is	  not	  tolerated	  by	  most	  of	  the	  selected	  DARPins.	  The	  V1	  loop	  deletion,	  in	  contrast,	  397	  
was	   tolerated	   by	   all	   groups.	   Deletion	   of	   the	   entire	   V1V2	   domain	   had	   a	   differential	   effect.	  398	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Selection	  I	  DARPin	  H3_1_B3	  failed	  to	  bind	  gp120ΔV1V2.	  Binding	  of	  the	  three	  Selection	  II	  DARPins	  399	  
3m3_A8,	  3m3_B9	  and	  3m3_F12	  was	  markedly	  reduced	  in	  absence	  of	  the	  V1V2	  domain,	  while	  400	  
the	  remaining	  DARPins	  bound	  equally	  well	  in	  presence	  and	  absence	  of	  the	  V1V2	  region.	  With	  a	  401	  
single	  exception	  (3m2_A12)	  deletion	  of	  the	  V3	   loop	   led	  to	  complete	  or	  near	  complete	   loss	  of	  402	  
DARPin	   binding.	   Thus,	   both	   the	   gp120I420R	  mutation	   and	   V3	   loop	   deletion	   inferred	   structural	  403	  
rearrangements	   in	  monomeric	  gp120	  which	  affected	  recognition	  by	  DARPins	  but	  were	   largely	  404	  
tolerated	  by	  gp120-­‐specific	  Abs.	  405	  
	  406	  
Inhibition	  of	  HIV	  entry	  by	  gp120-­‐specific	  DARPins	  407	  
We	  next	  evaluated	   the	  efficacy	  of	   the	  DARPins	   to	   inhibit	   entry	  of	  envelope-­‐pseudotyped	  HIV	  408	  
into	  TZM-­‐bl	  cells	   (46,	  60),	  probing	  a	  panel	  of	  Subtype	  B	  tier	  1	  (including	  highly	  neutralization-­‐409	  
sensitive	   V1V2-­‐deleted	   viruses)	   and	   tier	   2	   viruses	   (Figure	   5).	   We	   previously	   determined	   the	  410	  
inhibitory	  capacity	  of	  mAbs	  b12	  and	  2G12	  against	  the	  same	  virus	  panel	  (21,	  46)	  and	  these	  data	  411	  
are	   shown	   in	   comparison.	   The	   majority	   of	   DARPin	   clones	   portrayed	   a	   moderate	   to	   potent	  412	  
inhibition	  of	  the	  highly	  neutralization-­‐sensitive	  viruses	  lacking	  the	  V1V2	  domain	  and	  the	  tier	  1	  413	  
virus	  isolates	  NL4-­‐3	  and	  SF162	  but	  lacked	  activity	  against	  Tier	  2	  viruses.	  Notably,	  only	  one	  clone,	  414	  
5m3_D12,	  portrayed	  some	  breadth	  against	  tier	  2	  viruses.	  The	  same	  DARPin	  also	  blocked	  in	  vitro	  415	  
infection	  of	  activated	  macaque	  PBMCs	  with	  SHIV162P3	  (data	  not	  shown).	  None	  of	  the	  selected	  416	  
DARPin	  clones	  affected	  the	  entry	  of	  virions	  carrying	   the	  unrelated	  retroviral	  murine	   leukemia	  417	  
virus	   (MuLV)	   envelope,	   confirming	   that	   the	   observed	   inhibition	   by	   DARPins	   is	   indeed	   HIV-­‐418	  
specific.	  Interestingly,	  DARPins	  H3_1B3,	  3m3_B9	  and	  3m3_F12	  blocked	  wt	  NL4-­‐3	  and	  wt	  SF162	  419	  
but	   lost	   in	   neutralizing	   activity	   in	   absence	   of	   the	   V1V2	   loop.	   The	   latter	   is	   in	   line	   with	   our	  420	  
observation	   that	   these	   clones	   had	   a	   strongly	   reduced	   capacity	   to	   bind	   gp120ΔV1V2,	   indicating	  421	  
that	  they	  bind	  to	  domains	  on	  gp120	  encompassing	  the	  V1V2	  region.	  Similarly,	  3m3_A8	  showed	  422	  
decreased	  activity	   against	   SF162	  but	  not	  NL4-­‐3	   in	   the	  absence	  of	   the	  V1V2	  domain.	  DARPins	  423	  
AKNF1_10	   and	   AKNF1_14,	   selected	   against	   V1V2-­‐deleted	   JR-­‐FL	   gp120,	   neutralized	   tier	   1	  424	  
isolates	  and	  V1V2-­‐deleted	  viruses	  with	  high	  potency	  (low	  nanomolar	  to	  sub-­‐nanomolar	  range)	  425	  
but	   failed	   to	   block	   wild-­‐type	   tier	   2	   isolates	   with	   one	   exception,	   (6535.3	   neutralization	   by	  426	  
AKNF1_14).	  Thus,	  as	  can	  be	  expected	  from	  the	  panning	  against	  V1V2-­‐deleted	  gp120,	  DARPins	  427	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AKNF1_10	   and	  AKNF1_14	   are	   limited	   in	   their	   action	  by	  V1V2	   shielding.	  They	   can	  only	  access	  428	  
their	  binding	  domain	  when	  the	  envelope	  trimer	  has	  adopted	  an	  open,	  tier	  1	  like	  conformation	  429	  
for	  which	  V1V2	  shielding	  is	  less	  efficient	  or	  when	  the	  V1V2	  shielding	  is	  artificially	  removed,	  but	  430	  
not	  when	  the	  trimer	   is	   in	   the	  closed	  conformation	  adopted	  by	  tier	  2	  viruses.	  Despite	  the	  fact	  431	  
that	  all	  DARPins	  in	  Selection	  I	  and	  II	  were	  derived	  from	  selection	  against	  wild-­‐type	  JR-­‐FL	  gp120,	  432	  
only	  DARPin	  5m3_D12	  blocked	  entry	  of	  wild-­‐type	  JR-­‐FL	  efficiently.	  Since	  DARPin	  5m3_D12	  also	  433	  
showed	   the	   highest	   reactivity	   against	   tier-­‐2	   viruses	   probed	   in	   our	   panel,	  we	   focused	   for	   the	  434	  
remaining	  analysis	  on	  this	  clone.	  435	  
	  436	  
DARPin	  5m3_D12	  recognizes	  the	  V3	  loop	  437	  
To	   obtain	   further	   information	   on	   the	   epitope	   recognized	   by	   5m3_D12,	   we	   performed	  438	  
competition	  binding	  experiments	  using	  a	  panel	  of	  gp120-­‐directed	  mAbs	  specific	  for	  the	  gp120	  439	  
core,	   C-­‐terminus,	   	   CD4bs,	   CoRbs	   and	   the	  V3	   loop	  and	   the	   glycan-­‐dependent	  mAbs	  2G12	  and	  440	  
PGT128	  (Figure	  6).	  5m3_D12	  binding	  to	  gp120	  was	  only	  competed	  off	  by	  mAbs	  directed	  to	  the	  441	  
V3	   tip	   (447-­‐52D,	  1-­‐79).	  The	   fact	   that	  none	  of	   the	  other	  DARPins	  was	  affected	  by	   these	  mAbs	  442	  
and	   the	   failure	   of	   5m3_D12	   to	   bind	   to	   V3	   loop	   deleted	   gp120	   (Figure	   4)	   provided	   strong	  443	  
evidence	   that	   5m3_D12	   binds	   the	   V3	   loop	   directly.	  MAb	   PGT128	   which	   recognizes	   a	   glycan	  444	  
dependent	  motif	  at	  the	  V3	  stem	  region	  had	  in	  contrast	  to	  the	  tip	  specific	  mAbs	  only	  a	  marginal	  445	  
influence	   on	   5m3_D12	   binding.	  Of	   note,	   PGT128	   had	   a	  more	   substantial	   effect	   on	   all	   other	  446	  
DARPins	   in	  our	  panel	  suggesting	  that	  PGT128	  binding	  induces	  conformational	  rearrangements	  447	  
that	  afflict	  a	  variety	  of	  domains	  within	  gp120.	   In	   line	  with	  the	  CoRbs	  mutant	  analysis	  and	  the	  448	  
selection	  against	  a	  CD4	  liganded	  target,	  the	  CoRbs	  epitope	  directed	  mAb	  17b	  (and	  to	  a	   lesser	  449	  
extent	  mAb	   48d)	   affected	   binding	   of	   all	   DARPins	   from	   Selection	   II.	   Of	   note,	  5m3_D12	  which	  450	  
preferentially	  binds	  to	  CD4	  and	  CD4-­‐M47	  triggered	  gp120,	  failed	  to	  bind	  to	  gp120	  in	  presence	  451	  
of	  mAbs	  b12	  and	  b6	  but	  recognized	  gp120	  in	  presence	  of	  VRC01	  suggesting	  that	  the	  latter	  mAb	  452	  




DARPin	  5m3_D12	  recognizes	  the	  V3	  loop	  in	  a	  conformation-­‐dependent	  manner	  455	  
To	   define	  whether	  5m3_D12	   is	   indeed	   specific	   for	   the	   V3	   loop	  we	   performed	   direct	   binding	  456	  
studies	  and	  competition	  binding	  experiments,	  using	  both	  linear	  peptides	  and	  a	  panel	  of	  V3	  loop	  457	  
mimetics,	  based	  on	  structures	  in	  the	  Protein	  Data	  Bank	  (PDB)	  of	  V3	  loop	  peptides	  bound	  to	  the	  458	  
mAbs	  F425-­‐B4e8	   (29),	  2219	   (61),	  537-­‐10D	   (62)	  and	  447-­‐52D	   (63)	   (Figure	  7A).	  The	  peptides	   in	  459	  
each	  complex	  adopt	  β-­‐hairpin	  conformations,	  but	  differences	  arise	   in	   the	  orientations	  of	  side	  460	  
chains	  on	  each	  face	  of	  the	  hairpin	  (the	  register	  of	  the	  hairpin).	   In	  the	  complex	  with	  2219,	  the	  461	  
I307	  and	  F317	   side	   chains	  point	   to	   the	   same	   side	  of	   the	  hairpin	  and	   comprise	  a	   cross-­‐strand	  462	  
hydrogen-­‐bonding	  (HB)	  pair,	  whereas	  in	  the	  complex	  with	  F425-­‐B4e8,	  I307	  and	  Y318	  form	  the	  463	  
HB	  pair,	   and	  with	  537-­‐10D	   the	  bond	   is	  between	  H308	  and	  F317	   (Figure	  7A).	   In	  designing	   the	  464	  
mimetics,	   the	  V3	   loop	   sequences	  were	   transplanted	  onto	   a	  D-­‐Pro-­‐L-­‐Pro	   template	   in	   order	   to	  465	  
stabilize	   the	   backbone	   hairpin	   conformation	   and	   fix	   the	   hairpin	   register	   (64).	   The	   pair	   of	  466	  
residues	  directly	  attached	  to	  the	  template	  should	  orient	  their	  side	  chains	  onto	  the	  same	  face	  of	  467	  
the	  hairpin,	  and	  occupy	  a	  HB	  position.	  In	  this	  way,	  the	  four	  cyclic	  peptide	  mimetics	  referred	  to	  468	  
here	   as	  HF,	   IY,	   IF	   and	  HY	   (Figure	  7A)	  were	  designed,	  which	   should	   structurally	  mimic	   the	  V3	  469	  
peptides	   complexed	   with	   the	   respective	   mAbs.	   The	   IY	   mimetic	   was	   reported	   earlier	   (31),	  470	  
whereas	  the	  other	  mimetics	  studied	  here	  were	  produced	  and	  characterized	   in	  the	  same	  way.	  471	  
NMR	   structures	   of	   the	  mimetics	  were	   determined	   in	   aqueous	   solution,	  which	   confirmed	   the	  472	  
expected	  hairpin	  structures	  (Figures	  7A,	  S2,	  S3	  and	  Tables	  S1-­‐S5).	  All	  V3	  peptides	  comprised	  the	  473	  
conserved	  GPG	  motif	  at	  the	  tip	  of	  the	  loop	  as	  well	  as	  parts	  of	  the	  loop	  stem.	  474	  
We	   performed	   competition	   binding	   studies	   of	   5m3_D12	   binding	   to	   plate-­‐immobilized	   JR-­‐FL	  475	  
gp120	   triggered	   by	   CD4M47	   in	   the	   presence	   and	   absence	   of	   linear	   V3	   loop	   peptides	   and	  V3	  476	  
mimetics	  from	  strains	  JR-­‐FL	  and	  MN	  (Figure	  7B).	  	  Interestingly,	  5m3_D12	  portrayed	  a	  very	  clear	  477	  
preference	  for	  structurally	  arrested	  mimetics	  of	  the	   IY	  register,	  as	  these	  competed	  effectively	  478	  
with	  gp120	  for	  DARPin	  binding,	  whereas	  the	  linear	  peptides	  based	  on	  the	  same	  sequences	  did	  479	  
not.	  The	  mimetic	   IY	  (MNmut)	  which	  contains	  a	  proline	  to	  alanine	  substitution	  in	  the	  conserved	  480	  
GPG	  motif	  showed	  reduced	  competition	  (Figure	  7B).	  In	  contrast	  to	  IY	  mimetics,	  mimetics	  with	  481	  
HY	   and	   IF	   register	   did	   not	   compete	   off	   5m3_D12	   binding	   to	   gp120.	   The	   mimetics	   with	   HF	  482	  
register	   and	   the	   cyclic	   SS,	   a	   V3	   mimetic	   cyclized	   by	   a	   disulphide	   bond,	   showed	   weak	   to	  483	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moderate	  competition.	  Overall,	  the	  competition	  experiments	  highlighted	  a	  strong	  dependence	  484	  
of	   5m3_D12	   on	   a	   specific	   V3	   conformation,	   which	   is	   in	   sharp	   contrast	   to	   V3-­‐loop-­‐directed	  485	  
antibodies	  (31).	  Interestingly,	  the	  mAbs	  447-­‐52D	  (epitope	  model	  for	  the	  HY	  mimetic)	  and	  F425-­‐486	  
B4e8	  (epitope	  model	  for	  the	  IY	  mimetics)	  reacted	  equally	  well	  with	  the	   linear	  V3	  peptide	  and	  487	  
their	   modeled	   epitope	   mimetic,	   but	   showed	   a	   reduced	   efficacy	   in	   binding	   mimetics	   with	   a	  488	  
different	   register	   (Figure	   7C).	   We	   verified	   these	   findings	   by	   performing	   direct	   V3	   peptide	  489	  
binding	   experiments	   using	   plate-­‐immobilized	   biotinylated	   peptides.	   DARPin	   5m3_D12,	   but	  490	  
none	  of	  the	  DARPins	  from	  other	  groups	  (Figure	  8	  and	  data	  not	  shown),	  bound	  to	  the	  mimetic	  491	  
with	   IY	   register	   based	   on	   the	   V3	   sequence	   of	   the	  MN	   virus	   strain.	   Binding	   to	   the	   linear	   V3	  492	  
peptide	   from	   the	   same	   strain	   by	   the	   DARPin	   was	   approximately	   hundredfold	   weaker.	   In	  493	  
contrast,	   the	   V3-­‐specific	   mAbs	   1-­‐79	   (25),	   19b	   (65)	   and	   447-­‐52D	   bound	   both	   the	   linear	   and	  494	  
structurally	   arrested	   peptides	   at	   comparative	   levels	   with	   1-­‐79	   even	   displaying	   a	   slight	  495	  
preference	  for	  the	  linear	  peptide	  (Figure	  8).	  	  496	  
Most	  interestingly,	  DARPin	  5m3_D12	  is	  able	  to	  neutralize	  not	  only	  V1V2-­‐deleted	  JR-­‐FL	  but	  also	  497	  
wild-­‐type	   JR-­‐FL	  pseudotyped	  virus,	   albeit	  with	  2	   logs	   lower	  potency	   (Figure	  8).	   This	   contrasts	  498	  
with	  V3-­‐directed	  mAbs	  1-­‐79,	  19b	  and	  447-­‐52D	  which	  are	  more	  than	  5	  logs	  less	  potent	  against	  499	  
wild-­‐type	   JR-­‐FL,	   compared	   to	   V1V2-­‐deleted	   JR-­‐FL	   (Figure	   8).	   Since	   the	   V3	   loop	   is	   potently	  500	  
shielded	  against	  antibody	  attack	  by	  the	  V1V2	  domain,	  most	  V3	  loop	  antibodies	  defined	  to	  date	  501	  
cannot,	   or	   only	   with	   low	   efficacy,	   neutralize	   HIV	   (21).	   In	   the	   absence	   of	   V1V2	   shielding,	  502	  
however,	  V3	  loop	  antibodies	  display	  remarkable	  potency	  and	  cross	  reactivity	  (21).	  	  503	  
DARPin	  5m3_D12	  is	  thus	  able	  to	  partially	  circumvent	  V1V2	  shielding.	  Intriguingly,	  we	  observed	  504	  
a	  notable	  capacity	  of	  DARPin	  5m3_D12	  in	  blocking	  divergent	  strains	  of	  wild-­‐type	  HIV	  (Figure	  5).	  505	  
However,	  while	  our	  data	  suggest	  that	  5m3_D12	   is	  able	  to	  partially	  pass	  by	  the	  V1V2	  shielding	  506	  
on	   genetically	   divergent	   isolates,	   the	   activity	   of	   5m3_D12	   against	   viruses	   lacking	   the	   V1V2	  507	  
domain	  was	  still	  markedly	  enhanced,	  indicating	  that	  access	  of	  5m3_D12	  is	  also	  to	  some	  extent	  508	  
restricted	  by	  the	  V1V2	  shield.	  	  509	  
We	  next	  compared	   the	  neutralization	  breadth	  of	  5m3_D12	   to	  V3-­‐specific	  mAbs	  447-­‐52D	   (28)	  510	  
and	  1-­‐79	  against	  subtype	  B	  viruses	  (Figure	  9).	  Both	  mAbs	  recognize	  an	  epitope	  in	  the	  V3	  tip	  that	  511	  
is	  expected	  to	  at	  least	  partially	  overlap	  with	  the	  5m3_D12	  epitope	  (Figure	  6).	  DARPin	  5m3_D12	  512	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neutralized	  a	  subset	  of	  strains	  with	  considerable	  potency	  (Figure	  9,	  symbols	  in	  red),	  but	  showed	  513	  
no	   efficacy	   against	   the	   residual	   strains.	   Intriguingly,	   the	   majority	   of	   the	   strains	   which	   were	  514	  
sensitive	  to	  5m3_D12	  were	  also	  neutralized	  by	  mAb	  1-­‐79	  but	  not	  mAb	  447-­‐52D,	  indicating	  also	  515	  
distinct	  differences	  amongst	  V3	  loop	  antibodies	  in	  bypassing	  V1V2	  shielding.	  516	  
To	  obtain	  insights	  into	  the	  binding	  properties	  of	  5m3_D12	  in	  the	  context	  of	  the	  native	  envelope	  517	  
spike	   during	   virus	   entry,	   we	   next	   performed	   competition	   inhibition	   experiments	   using	   V3	  518	  
peptides	   and	  mimetics.	   Neutralization	   activity	   of	   DARPin	  5m3_D12	   against	   SF162	   and	   V1V2-­‐519	  
deleted	   JR-­‐FL	   pseudotyped	   virus	   was	   diminished	   by	   addition	   of	   V3	   IY	   mimetics	   in	   a	   dose-­‐520	  
dependent	   fashion,	   whereas	   the	   corresponding	   linear	   peptides	   and	   the	   mimetic	   with	   HF3	  521	  
register	  showed	  no	  effect	  (Figure	  10).	  This	  contrasted	  with	  the	  pattern	  observed	  for	  mAb	  1-­‐79,	  522	  
where	   neutralization	   activity	   was	   more	   strongly	   affected	   by	   addition	   of	   linear	   V3	   peptides	  523	  
compared	  to	  V3	  mimetics	  of	  the	  IY	  register.	  A	  V3	  mimetic	  with	  HF	  register	  had	  an	  intermediate	  524	  
effect.	   In	   summary,	   these	   experiments	   underlined	   that	   DARPin	   5m3_D12	   recognizes	   the	   V3	  525	  
loop	  in	  a	  structurally	  constrained	  manner.	  	  526	  
	  527	  
Discussion	  528	  
HIV	   has	   evolved	   an	   array	   of	   schemes,	   foremost	   heavy	   glycosylation	   and	   conformational	  529	  
masking,	  	  to	  shield	  vulnerable	  sites	  on	  the	  envelope	  trimer	  from	  immune	  recognition	  and	  attack	  530	  
by	  neutralizing	  antibodies	   to	  persevere	   functionality	  of	   the	  entry	  complex	   (8,	  10).	  Engineered	  531	  
entry	   inhibitors	   at	   large	   suffer	   from	   the	   same	   limitations	   as	   antibodies	   in	   accessing	   relevant	  532	  
domains	   on	   the	   envelope	   trimer.	   In	   the	   present	   study	   we	   investigated	   the	   potential	   of	   the	  533	  
DARPin	  technology	   in	  selecting	  novel	  gp120-­‐reactive	  entry	   inhibitors.	  Both	  antibodies	  and	  the	  534	  
smaller	   sized	   DARPins	   harbor	   the	   ability	   to	   recognize	   their	   targets	   with	   high	   affinity	   and	  535	  
specificity,	   while	   differing	   entirely	   in	   structure	   (19).	   We	   reasoned	   that	   the	   distinct	   binding	  536	  
properties	   of	   DARPins	   may	   allow	   the	   selection	   of	   novel	   gp120-­‐reactive	   molecules	   with	  537	  
specificities	  in	  epitope	  recognition	  and	  inhibitory	  activity	  that	  differ	  from	  those	  found	  amongst	  538	  
neutralizing	   antibodies.	   Antibodies	   and	   the	  N2C	   (15	   kDa)	   and	  N3C	   (18	   kDa)	   type	   of	   DARPins	  539	  
employed	  in	  the	  present	  study	  cover	  a	  comparably	  sized	  binding	  footprint.	  DARPins	  recognize	  540	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the	  target	  by	  using	  their	  surface	  of	  α-­‐helices	  and	  their	  row	  of	  β-­‐hairpins,	  resulting	  in	  a	  groove-­‐541	  
like	  binding	  surface,	  and	  thus	  they	  prefer	  to	  bind	  to	  the	  surface	  of	  a	  globular	  protein	  domain,	  or	  542	  
at	  least	  structurally	  well	  defined	  loops	  (16-­‐18,	  66-­‐68).	  Antibodies	  can	  do	  this,	  too,	  but	  they	  can	  543	  
also	  bind	  to	  an	  unstructured	  terminal	  peptide	  or	  long	  loop,	  which	  adapts	  to	  a	  pocket	  or	  groove	  544	  
between	   the	  antibody	  variable	  domains.	  Conversely,	   the	  complementary	  determining	   regions	  545	  
(CDRs)	  of	  the	  antibody,	  especially	  a	   long	  CDR-­‐H3,	  can	  bind	  within	  a	  pocket	  of	  the	  target	  or	  at	  546	  
the	   side	   of	   a	   domain	   (69).	   The	   preference	   of	  DARPins	   for	   recognizing	   structural	   components	  547	  
could	   be	   advantageous	   in	   selecting	   HIV	   envelope-­‐directed	   inhibitors,	   particularly,	   as	   recent	  548	  
findings	   of	   potent	   broadly	   active	   neutralizing	   antibodies	   revealed	   a	   high	   prevalence	   of	  549	  
antibodies	   recognizing	   conformational,	   inter-­‐	   and	   intra-­‐protomer	   loop-­‐spanning	   binding	  550	  
domains	  (70,	  71).	  DARPins	  also	  have	  many	  favorable	  biophysical	  properties,	  such	  as	  exceptional	  551	  
stability	   and	   high-­‐yield	   prokaryotic	   production,	   which,	   if	   broad	   and	   potent	   HIV	   envelope-­‐552	  
specific	  DARPin	   inhibitors	  are	   found,	   renders	   this	   type	  of	  molecule	  a	  promising	  candidate	   for	  553	  
use	  as	  topical	  microbicide.	  554	  
In	  the	  present	  study	  we	  selected	  HIV	  entry-­‐blocking	  clones	  from	  DARPin	  libraries	  via	  ribosome	  555	  
display	   in	   which	   gp120	   was	   presented	   as	   panning	   target	   in	   four	   modifications	   aiming	   to	  556	  
investigate	  the	  influence	  of	  gp120	  conformational	  flexibility	  and	  glycosylation	  on	  the	  efficacy	  of	  557	  
DARPin	   selection.	   	  We	   found	   that	  DARPins	  have	  a	   relatively	   limited	  capacity	   to	   recognize	   the	  558	  
wild-­‐type,	   conformationally	   flexible	   gp120	   envelope	   glycoprotein.	   Of	   the	   four	   gp120	  559	  
modifications	   probed,	   only	   gp120	   liganded	   with	   the	   CD4M47	   miniprotein	   (and	   thereby	  560	  
structurally	  arrested)	  yielded	  a	  broader	  range	  of	  DARPin	  binders	  recognizing	  different	  epitopes.	  561	  
Common	  to	  all	  selected	  gp120-­‐reactive	  DARPins	  was	  a	  relatively	  strong	  dependence	  on	  specific	  562	  
gp120	   conformations.	   This	   was	   particularly	   evident	   in	   the	   mutant	   gp120	   mapping	   we	  563	  
performed.	   The	   CoRbs	   mutant	   gp120I420R	   and	   the	   V3	   loop	   deletion	   variant	   were,	   with	   one	  564	  
exception,	  each	  not	   recognized	  by	   the	   selected	  DARPins,	   irrespective	  of	  which	   selection	   they	  565	  
came	  from,	  while	  gp120-­‐specific	  antibodies	  recognized	  the	  same	  mutant	  proteins	  unless	  their	  566	  
epitope	  was	  known	  to	  be	  directly	  affected	  by	  the	  inferred	  mutations	  (Figure	  4).	  	  567	  
Preferences	   regarding	   specific	   gp120	   conformations	   were	   also	   apparent	   amongst	   DARPins	  568	  
selected	  against	  CD4M47-­‐liganded	  gp120.	  Only	   the	  V3-­‐loop-­‐specific	  N3C	  clone	  5m3_D12	  was	  569	  
	  22	  
	  
able	  to	  bind	  to	  non-­‐liganded	  gp120.	  All	  other	  DARPins	  derived	  from	  this	  selection	  series	  require	  570	  
CD4	  ligation	  (by	  either	  sCD4	  or	  the	  CD4	  mini-­‐protein	  CD4M47)	  in	  order	  to	  bind	  to	  gp120.	  	  571	  
The	  V3-­‐specific	  DARPin	   5m3_D12	  was	   the	  only	  DARPin	  we	  selected	  with	  a	  notable	  activity	   to	  572	  
block	  Subtype	  B	  tier	  2	  virus	  infection.	  Even	  though	  this	  activity	  was	  limited	  to	  a	  relatively	  small	  573	  
number	  of	   isolates	   this	   is	  noteworthy,	  considering	   that	  V3-­‐loop-­‐specific	  antibodies	  commonly	  574	  
fail	  to	  inhibit	  these	  types	  of	  isolates,	  as	  they	  cannot	  bypass	  V1V2	  shielding	  (21).	  Thus,	  although	  575	  
5m3_D12	  is	  to	  some	  extent	  restricted	  by	  V1V2	  shielding,	  it	  interacts	  with	  the	  V3	  loop	  of	  certain	  576	  
subtype	   B	   tier	   2	   isolates	   in	   a	   way	   that	   allows	   bypassing	   of	   the	   V1V2	   shield	   and	   effective	  577	  
inhibition	   of	   entry.	   Investigations	   of	   the	   breadth	   of	   5m3_D12	   against	   viruses	   from	   other	  578	  
subtypes	  are	  currently	  underway.	  579	  
In	   stark	   contrast	   to	   the	   interaction	  of	  V3	   loop	  antibodies	  with	   their	   epitope	  on	  V3	  5m3_D12	  580	  
depends	  however	  on	  a	  specific	  conformation	  of	  the	  V3	  loop	  domain	  in	  order	  to	  recognize	  the	  581	  
loop	  and	  to	  block	   infection.	  The	  preference	  of	  DARPin	   5m3_D12	   for	  a	  mimetic	  structure	  with	  582	  
the	   IY	   register	   (31)	   	   suggest	   that	   the	   IY	   β-­‐hairpin	   structure	   is	   close	   to	   the	   predominant	  583	  
conformation	   the	   gp120	   V3	   loop	   adopts	   after	   CD4	   binding.	   Both	   epitope	   binding	   and	  584	  
neutralization	  activity	  of	  5m3_D12	   crucially	   relied	  on	   this	  V3	   loop	   conformation.	  Overall,	   our	  585	  
findings	   highlight	   that	   the	   preference	   of	   DARPins	   to	   recognize	   specific	   structures	   may	   be	  586	  
utilized	   in	   further	   selection	   strategies	   to	   their	   advantage.	   Mimetics	   as	   employed	   here	   bear	  587	  
promise	  as	  targets	  for	  selections	  as	  they	  could	  allow	  to	  more	  efficiently	  steer	  DARPin	  selection	  588	  
towards	  a	  specific	  site.	  	  589	  
In	   summary,	   our	   study	   highlights	   the	   potential	   of	   the	   DARPin	   technology	   in	   retrieving	   HIV	  590	  
envelope-­‐reactive	   binders	   with	   unique	   properties,	   which	   harbor	   entry	   inhibitory	   capacity.	   In	  591	  
particular,	   the	   conformation	   dependence	   of	   the	   DARPin-­‐target	   interaction	   may	   prove	   of	  592	  
advantage	  for	  selecting	  potent	  entry	  inhibitors	  with	  novel	  specificities,	  including	  alternatives	  to	  593	  
quaternary	   antibodies	   (72,	   73).	   Once	   identified,	   HIV	   specific	   DARPin	   binders	   with	   inhibitory	  594	  
activity	  open	  multiple	  avenues	  for	  improving	  their	  potency.	  Besides	  refined	  affinity	  maturation,	  595	  
multivalent	  constructs	  (of	  DARPins	  with	  one	  or	  more	  specificities)	  to	  crosslink	  subunits	  within	  a	  596	  
trimer	  or	  neighboring	  trimers	  bear	  promise	  in	  boosting	  efficacy	  (74).	  	  597	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With	  the	  increasing	  understanding	  of	  the	  architecture	  of	  the	  viral	  spike	  (21,	  75,	  76),	  possibilities	  598	  
to	   generate	   stable	   soluble	   trimers	   which	   closely	   resemble	   the	   native	   spike	   (77,	   78)	   and	   the	  599	  
means	   to	   generate	   structurally	   arrested	   peptide	   mimetics	   of	   gp120	   micro-­‐domains	   (31),	   a	  600	  
number	  of	  tools	  have	  become	  available	  which	  bear	  promise	  to	  tailor	  future	  DARPin	  selections	  601	  
to	  specific	  domains	  of	  interest.	  As	  discussed	  above,	  based	  on	  our	  current	  data	  the	  latter	  holds	  602	  
particular	   promise	   to	   improve	   envelope-­‐specific	   DARPin	   identification	   and	   to	   harness	   the	  603	  
distinctive	  binding	  properties	  of	  DARPins	  for	  HIV	  inhibitor	  development.	  	  604	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Table	  A1.	  Alignment	  of	  V3	  sequences	  of	  virus	   isolates	  probed	  in	  Figures	  5	  and	  9.	  (Amino	  acid	  613	  
positions	  numbering	  according	  to	  HXB2).	  	  614	  
 615	  
 616	  
Table	  A1	   V3	  loop	  sequence	  
	   	     300       310       320       330            












JR-­‐FL	  	  	  	  	  	  	  	  	   CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC  
RHPA4259.7	  	  	  	   ...H........N........A..K..........  
NAB1pre-­‐cl_39x	  	  	   ....S.......T........A.........K...  
NAB2pre-­‐cl_3	   ...L.....R..N......W.....V.....K.N.  
NAB10pre-­‐cl_2	  	  	  	   ............R....S.............K...  













6535.3	  	  	  	  	  	  	  	   ............NL.......A..D..........  
AC10.0.29	  	  	  	  	   .I........G.............D..........  
CAAN5342.A2	  	  	   ........S...T........A..R......K...  
PVO.4	  	  	  	  	  	  	  	  	   ............S........A..D..........  
QH0692.42	  	  	  	  	   ....G................A..D..........  
REJO4541.67	  	  	   ..............A......A.........K.Y.  
SC422661	  	  	  	  	  	   ..........G.T.....V...-...V.....V..  
THRO4156.18	  	  	   ........S....M...G..FA..R......K.Y.  
TRO.11	  	  	  	  	  	  	  	   .........R...........A..D..........  
WITO4160.33	  	  	   ....G....R..N........A..A......K...  
NAB3pre-­‐cl_43	  	  	  	  	  	  	   .....................A..A...N......  
NAB4pre-­‐cl_1	  	  	  	  	   .........R..P........A.-D..........  
NAB5pre-­‐cl_1	  	  	  	  	   ....S....R..T........A..D......K...  
ZA110_10.14	  	  	   ....S....R.......K....-.G..........  
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Figure	  1:	  Selection	  strategies	  employed	  for	  the	  generation	  of	  gp120-­‐specific	  DARPins	  	  887	  
A)	  Schematic	  view	  of	  a	  ribosome	  display	  DARPin	  selection	  round.	  B)	  The	  four	  employed	  DARPin	  888	  
selection	  strategies	  and	  numbers	  of	  obtained	  gp120-­‐specific	  binders	  are	  shown.	  *	  3	  clones	  in	  889	  
Selection	  III	  and	  1	  clone	  in	  Selection	  IV	  with	  borderline	  reactivity	  for	  gp120	  were	  detected	  which	  890	  
had,	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  too	  low	  an	  affinity	  (	  >10µM)	  for	  further	  analysis.	  891	  
	  892	  
Figure	  2:	  Phylogenetic	  analysis	  of	  gp120-­‐specific	  DARPin	  clones	  derived	  by	  different	  selection	  893	  
approaches.	  	  894	  
Sequence	  relationships	  of	  clones	  obtained	  from	  four	  different	  selection	  strategies	  are	  shown	  as	  895	  
phylogenetic	   trees	   derived	   using	   the	  Maximum	   Likelihood	  method	   based	   on	   the	   JTT	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based	  model.	  Data	   are	  based	  on	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   alignments	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  and	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  binders	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each	  respective	  selection.	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  generation	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  black	  and	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  generation	  binders	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in	  blue.	  Binders	   shown	  with	   inverse	  colored	  boxes	  were	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   to	  be	  analyzed	   in	  detail.	   The	  899	  
trees	  are	  drawn	  to	  scale,	  with	  branch	  lengths	  measured	  in	  the	  number	  of	  substitutions	  per	  site.	  	  	  900	  
	  901	  
Figure	  3:	  DARPin	  binding:	  Analysis	  of	  specificity	  to	  gp120	  902	  
Overview	   of	   binding	   strength	   of	   individual,	   purified	   DARPin	   clones	   obtained	   from	   different	  903	  
selection	  strategies	  to	  gp120	  and	  derivatives	  as	  assessed	  by	  ELISA.	  Shown	  is	  the	  half-­‐maximal-­‐904	  
binding	  concentration	  for	  each	  of	  the	  gp120-­‐specific	  DARPin	  binders,	  as	  estimated	  by	  ELISA	  to	  905	  
recombinant	  gp120	   (JR-­‐FL)	  wild	   type	   (green),	   in	  complex	  with	  CD4	   (blue)	  or	  CD4M47	   (red)	  or	  906	  
V1V2-­‐loop-­‐deleted	   gp120JR-­‐FL	   (orange).	   No	   bar	   is	   depicted	   when	   no	   binding	   to	   a	   respective	  907	  
construct	  was	  detected	  up	  to	  a	  concentration	  of	  4	  µM.	  Error	  bars	  indicate	  the	  standard	  error	  of	  908	  
the	  mean	  (SEM).	  909	  
	  910	  
	  911	  
Figure	  4:	  DARPin	  mapping:	  Reactivity	  with	  mutant	  gp120	  proteins	  	  912	  
Binding	   of	   gp120-­‐specific	   mAbs	   (A)	   and	   DARPins	   (B)	   to	   the	   indicated	   JR-­‐FL-­‐derived	   gp120	  913	  
proteins	   by	   ELISA.	   The	   ELISA	   binding	   signal	   of	   DARPins	   and	  mAbs	   to	  wt	   gp120	   at	   saturating	  914	  
concentration	   is	   set	   to	  100%	  and	  mutant	  gp120	  binding	   is	  depicted	  relative	   to	   this	  value.	  For	  915	  
clones	  that	  only	  bind	  gp120	  in	  a	  liganded	  form,	  the	  CD4	  ligand	  was	  used	  in	  each	  ELISA.	  Since	  the	  916	  
CD4	  ligands	  do	  not	  bind	  gp120D368R,	  this	  construct	  could	  not	  be	  employed	  in	  the	  liganded	  form.	  917	  
Heat	  maps	  indicate	  100%	  binding	  like	  wt	  in	  green	  and	  no	  binding	  in	  red	  with	  a	  linear	  gradient	  918	  
through	  yellow	  at	  50%.	  (n/a,	  not	  applicable;	  n/d,	  not	  done).	  	  919	  
	  920	  
Figure	  5:	  HIV	  Entry	  inhibition	  by	  gp120-­‐specific	  DARPins	  	  921	  
DARPin	  inhibition	  of	  a	  panel	  of	  21	  env	  pseudotyped	  viruses	  of	  tier	  1	  (wt	  and	  V1V2-­‐deleted),	  tier	  922	  
2	  and	  MuLV	  as	  control	  was	  probed	  in	  the	  TZM-­‐bl	  assay.	  The	  50%	  inhibitory	  concentration	  (IC50)	  923	  
values	   are	   depicted.	   V1V2-­‐deleted	   virus	   envelopes	   are	   shown	   in	   red,	   wt	   tier	   1	   envelopes	   in	  924	  
blue,	  wt	   tier	  2	  envelopes	   in	  black	  and	  the	  MuLV	  control	   in	  purple.	  For	  comparison,	   inhibition	  925	  
data	  of	   the	  mAbs	   IgG1-­‐b12	   and	  2G12	   from	  Rusert	   et	   al	   (21,	   46)	   are	   depicted.	  DARPins	  were	  926	  




Figure	  6:	  DARPin	  mapping:	  Reactivity	  with	  gp120	  in	  the	  presence	  of	  gp120-­‐specific	  mAbs	  	  929	  
Binding	   of	   DARPins	   to	   wt	   JR-­‐FL	   gp120	   (CD4-­‐triggered	   or	   not,	   as	   indicated)	   in	   ELISA	   in	   the	  930	  
presence	   of	   the	   depicted	   gp120-­‐specific	   mAbs	   was	   monitored.	   “None”	   indicates	   binding	   to	  931	  
gp120	  in	  the	  absence	  of	  competitor	  mAb	  and	  is	  set	  to	  100%.	  Binding	  signal	  in	  the	  presence	  of	  932	  
the	  competing	  mAbs	  is	  expressed	  relative	  to	  this	  value.	  For	  clones	  that	  only	  bind	  gp120	  when	  933	  
liganded,	  binding	  in	  the	  presence	  of	  the	  CD4	  ligand	  is	  set	  to	  100%.	  Ligands	  were	  not	  employed	  934	  
if	   they	   target	   the	   same	  epitope	  as	   the	  used	   competitor.	  Heat	  map	   indicates	  100%	  binding	   in	  935	  
absence	   of	   competitor	   in	   green	   and	   complete	   inhibition	   (0%	   binding)	   binding	   in	   red	   with	   a	  936	  
linear	  gradient	  through	  yellow	  at	  50%.	  (n/a,	  not	  applicable;	  n/d,	  not	  done).	  	  937	  
	  938	  
	  939	  
Figure	  7:	  DARPin	  5m3_D12	  interacts	  preferentially	  with	  structural	  mimetics	  of	  the	  V3	  loop	  940	  
(A)	  Top	  row:	  Backbone	  ribbon	  representations	  of	   linear	  V3	  peptides	  bound	  to	   the	  mAbs	  537-­‐941	  
10D,	  F425-­‐B4e8,	  2219	  and	  447-­‐52D	  (from	  PDB	  files	  3GHE,	  2QSC,	  2B0S	  and	  2ESX).	  The	  C(ß)	  atom	  942	  
of	  selected	  side	  chains	  are	  shown	  with	  a	  ball,	  and	  the	  residues	  shown	  are	  color	  coded.	  Cross-­‐943	  
strand	   hydrogen-­‐bonded	   residues	   are	   indicated	   by	   light	   blue	   dotted	   lines.	   Middle	   row:	   The	  944	  
designed	  backbone	  cyclic	  V3	   loop	  mimetics,	  with	  the	  HF,	   IY,	   IF	  and	  HY	  registers.	  Bottom	  row:	  945	  
Representative	  solution	  NMR	  structures	  determined	  for	  each	  mimetic,	  which	  confirm	  for	  each	  a	  946	  
stable	   ß-­‐hairpin	   backbone	   conformation	   and	   the	   predicted	   hairpin	   registers.	   The	  D-­‐Pro-­‐L-­‐Pro	  947	  
template	   is	   shown	   for	   each	   at	   the	   bottom	   of	   the	   structure	   in	   orange	   color.	   (B)	   Binding	   of	  948	  
DARPin	  5m3_D12	  to	  immobilized	  recombinant	  JR-­‐FL	  gp120-­‐liganded	  with	  CD4	  mimetic	  CD4M47	  949	  
was	  studied	  by	  ELISA	  in	  the	  presence	  of	  increasing	  concentrations	  of	  linear	  V3	  peptides	  and	  V3	  950	  
mimetics.	  Data	  are	   shown	  relative	   to	  5m3_D12	  binding	  without	  competitor	  peptides.	   (C)	  The	  951	  






Figure	   8:	  DARPin	   5m3_D12	   interacts	   preferentially	  with	   structural	  mimetics	   of	   the	  V3	   loop	  956	  
and	  inhibits	  entry	  of	  tier	  2	  virus	  JR-­‐FL	  957	  
Direct	   binding	   (left	   column)	   to	   plate-­‐immobilized	   linear	   MN	   V3	   peptide	   (black	   squares)	   and	  958	  
cyclic	  IY	  MN	  V3	  mimetic	  (green	  dots)	  in	  ELISA	  and	  entry	  inhibition	  in	  TZM-­‐bl	  cells	  (right	  column)	  959	  
of	   pseudoviruses	   JR-­‐FL	   (blue	   dots)	   and	   JR-­‐FL∆V1V2	   (red	   squares)	   by	   DARPin	   5m3_D12	   (first	  960	  
row),	  mAb	  1-­‐79	  (second	  row),	  mAb	  19b	  (third	  row)	  and	  mAb	  447-­‐52D	  (fourth	  row).	  	  961	  
	  962	  
Figure	   9:	   Subtype	   B	   tier	   2	   inhibition	   by	   DARPin	   5m3_D12	   and	   V3-­‐specific	   mAbs	  963	  
Neutralization	   breadth	   against	   subtype	   B	   tier	   2	   viruses	   of	   DARPin	   5m3_D12	   and	   V3-­‐specific	  964	  
monoclonal	  antibodies	  1-­‐79	  and	  447-­‐52D	  was	  probed	  in	  the	  TZM-­‐bl	  pseudotype	  virus	  inhibition	  965	  
assays.	  IC50	  values	  are	  recorded.	  Isolates	  inhibited	  by	  DARPin	  5m3_D12	  are	  shown	  in	  red.	  966	  
	  967	  
Figure	  10:	  IY	  V3	  loop	  mimetics	  efficiently	  compete	  with	  native	  V3	  loop	  on	  intact	  viral	  spikes	  968	  
for	  binding	  to	  DARPin	  5m3_D12	  969	  
Inhibitory	   activity	   in	   the	   TZM-­‐bl	   assay	  of	  DARPin	  5m3_D12	   (bottom	   row)	   and	  mAb	  1-­‐79	   (top	  970	  
row)	  against	  pseudoviruses	  JR-­‐FLΔV1V2	  (left	  column)	  and	  SF162	  (right	  column)	  was	  assessed	  in	  971	  
the	  presence	  and	  absence	  of	  competing	  linear	  V3	  peptides	  and	  cyclic	  V3	  mimetics.	  972	  
